Search the Newsreel

Spruce Biosciences: Q4 Biologics Filing Anticipated; Child Study Expected

Spruce Biosciences receives $5.5M from patient advocacy groups

Spruce Biosciences (NASDAQ:SPRB) has secured a $5.5 million strategic investment from the Cure Sanfilippo Foundation and the National MPS Society. This funding will partially support an expanded access program for its investigational therapy, tralesinidase alfa enzyme replacement therapy (TA-ERT), aimed at patients with Sanfilippo …

Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living with Tardive Dyskinesia

Neurocrine Biosciences announced the publication of KINECT-PRO™ Phase 4 study results, showing that INGREZZA® (valbenazine) capsules significantly improved patient-reported quality of life and daily functioning, alongside clinician-rated tardive dyskinesia (TD) movement severity. These improvements were seen across various patient demographics, including those with mild …

Neurocrine slips on safety issues linked to Vykat XR (NBIX:NASDAQ)

Neurocrine Biosciences' shares fell following resurfacing safety concerns related to Vykat XR, a rare disease therapy acquired through Soleno Therapeutics. Reports of potential fatalities and severe side effects, such as edema, have been linked to the drug, though a definitive causal link has not …

Cogent Biosciences, Inc. (NASDAQ:COGT) Given Average Recommendation of "Moderate Buy" by Brokerages

Cogent Biosciences (NASDAQ:COGT) has received an average "Moderate Buy" recommendation from thirteen brokerages, with an average 12-month price target of $45.90. The company recently reported quarterly EPS of -$0.52, exceeding the consensus estimate. Institutional investors have also increased their holdings in the company.

HC Wainwright Has Positive Estimate for SLDB Q3 Earnings

HC Wainwright has revised its Q3 2026 earnings estimate for Solid Biosciences (NASDAQ:SLDB), predicting a narrowed loss of $0.38 per share and maintaining a "Buy" rating with a $25 price target. The firm anticipates Solid Biosciences will become profitable by 2029, projecting earnings of …

Rapid Micro Biosystems, Inc. (NASDAQ:RPID) Just Reported Earnings, And Analysts Cut Their Target Price

Analysts Offer Predictions for AURA Q1 Earnings

Equities Analysts Set Expectations for PCRX Q3 Earnings

Aroa Biosurgery (ASX:ARX) Profit Milestone Shifts Focus to US Growth Strategy

Junshi Biosciences Sets August Board Meeting to Approve Interim 2026 Results

Regencell Bioscience Holdings Ltd (RGC) Earnings Forecast: Future EPS & Revenue Growth Estimates

(PCRX) and the Role of Price-Sensitive Allocations

This article analyzes Pacira Biosciences Inc

Beijing Biostar Pharmaceuticals Sets Board Meeting to Review Interim Results and Dividend

Renaissance Technologies LLC Boosts Holdings in Jade Biosciences, Inc. $JBIO

Neurocrine Biosciences rare disease drug possibly tied to safety issues, experts say

A group of physicians and experts in Prader-Willi syndrome has notified clinicians about a series of patient deaths and severe side effects potentially linked to Neurocrine Biosciences' newly approved drug, Vykat XR. Approved in March 2025, Vykat XR is intended to manage intense hunger …

Biotech Stocks At 52-Week Highs - ALMR +30% On Q2 Reports, DYN, CGEM, DXCM, CAH

(RTTNews) - The following biotech stocks reached a 52-week high on August 11, 2026, driven up by key catalysts such as positive quarterly or full year reports. Alamar Biosciences Inc. (ALMR) Alamar Biosciences is a proteomics company that has develops a liquid biopsy platform …

E. Ohman J or Asset Management AB Makes New Investment in Twist Bioscience Corporation $TWST

E. Ohman J or Asset Management AB has initiated a new position in Twist Bioscience Corporation, acquiring 8,287 shares valued at approximately $853,000. This investment comes as other major institutional investors, such as ARK Investment Management and Millennium Management, have also increased their holdings …

BofA Securities Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Cuts Target Price to $39

BofA Securities has reiterated its Buy rating for TYRA BIOSCIENCES, INC. (TYRA.US) but has revised its price target downward to $39. This adjustment reflects an updated outlook from the firm regarding the company's valuation.

Harvard Bioscience Releases Q2 2026 Financial Results

Harvard Bioscience (HBIO) reported its Q2 2026 financial results, showing a narrower-than-expected adjusted loss of $0.14 per share, beating analyst estimates. Revenue increased by 10.7% to $22.7 million. The company attributes this improvement to steady demand for its laboratory equipment and instruments, reflecting stabilization …

Village Farms International And 2 Other Penny Stocks Worth Watching

This article highlights three penny stocks—Village Farms International (VFF), NovaBridge Biosciences (NBP), and Quanterix (QTRX)—as potential investment opportunities. It details each company's financial health, operational focus, recent performance, and growth prospects, emphasizing their unique positions within their respective markets. The market as a whole …

Harvard Bioscience, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:HBIO) 2026-08-12

Harvard Bioscience, Inc. (HBIO) published its slide deck in conjunction with its Q2 2026 earnings call. The company reported an EPS of -$0.14, beating estimates by $0.07, and revenue of $22.73M, which was an 11.13% year-over-year increase and beat by $1.28M. This article provides …

Alamar Biosciences (ALMR): Qiming funds report over 10% ownership stake

Qiming funds have reported a significant ownership stake in Alamar Biosciences, Inc. (ALMR) through a Schedule 13G filing. Qiming Corporate GP VI, Ltd and related entities collectively hold 10.2% beneficial ownership, translating to 7,066,573 shares based on 69,311,186 shares outstanding as of April 30, …

Jade Biosciences Is Maintained at Buy by BTIG

BTIG has reiterated its "Buy" rating for Jade Biosciences. This indicates continued confidence from the firm in the company's stock performance.

Form 8K Solid Biosciences LLC For: 6 August By Investing.com

This article reports on Solid Biosciences LLC's Form 8K filing for August 6th. It is a brief announcement from Investing.com, providing only the date of the filing and the company involved. The article includes various market data and news unrelated to the specific Form …

Twist Bioscience (TWST) stake of 3.5% reported by William Blair Investment Management

William Blair Investment Management, LLC has reported a 3.5% beneficial ownership stake in Twist Bioscience Corp (TWST), totaling 2,174,594 shares. This filing, a Schedule 13G/A, indicates that the investment firm has sole voting power over 1,975,454 shares and sole dispositive power over all 2,174,594 …

Cytek Biosciences: Recurring Revenue Reaches 35% Of Sales As Installed Base Approaches 4,000 Instruments

Cytek Biosciences is seeing its recurring revenue, from service and reagent sales, grow as it expands its global installed base of instruments and introduces new cell-analysis platforms. Recurring revenue now accounts for 35% of total sales on a trailing 12-month basis, up from 32% …

Regencell Bioscience (RGC) Short Interest & Short Float | Updated Aug 2026 $RGC

Regencell Bioscience (RGC) had a short interest of 903,042 shares as of July 31, 2026, which is a 2.91% decrease from the previous report. This represents 0.18% of its public float, with a short interest ratio of 4.1 days to cover. The article provides …

Alamar Biosciences Shares (ALMR) Surge 31% as Consumables Drive Gross Margin Up

Alamar Biosciences (ALMR) shares surged 31% after reporting an 82% increase in second-quarter revenue, primarily driven by a 147% surge in consumable sales. Consumables now account for 52.6% of revenue, boosting gross margin to 60%. Despite continued operating losses, the company's strong revenue growth …

IDEAYA Biosciences (IDYA) Short Interest & Short Float | Updated Aug 2026

IDEAYA Biosciences (IDYA) reported a short interest of 10.11 million shares as of July 31, 2026, marking a 5.64% increase from the previous period. This represents 12.08% of the public float and a short interest ratio of 13.2 days to cover. The article provides …

Forte Biosciences (FBRX) investor Glazer Capital now holds 1.46% stake

PACIFIC BIOSCIENCES (PACB) CEO granted 1.97M options and 489K RSUs

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) CEO Mark Van Oene was granted 1.97 million stock options and 489,130 Restricted Stock Units (RSUs) on August 10, 2026. The stock options have an exercise price of $1.15 per share and vest over 36 monthly installments, while …

Pacira BioSciences (PCRX) Is Down 7.1% After Advancing PCRX-201 Gene Therapy With Positive Phase 1 Data

Pacira BioSciences' stock (PCRX) fell 7.1% despite advancing its PCRX-201 gene therapy for knee osteoarthritis into Phase 2 following positive two-year Phase 1 data. The company also announced revised full-year revenue expectations of US$735 million to US$760 million, down from prior guidance, but reported …

Harvard Bioscience (NASDAQ: HBIO) grows Q2 sales but faces higher debt costs

Harvard Bioscience (NASDAQ: HBIO) reported an 11.1% increase in Q2 2026 revenue, reaching $22.7 million, primarily driven by strong sales to CROs in the Americas and distributors in Asia-Pacific. Despite revenue growth and ongoing cost-saving initiatives like "Project Viking," the company posted a net …

HARVARD BIOSCIENCE INC 2026: Revenue $22.73M, EPS ($0.64) — 10-Q Summary

HARVARD BIOSCIENCE INC (HBIO) reported its second-quarter 2026 results, showing an 11.1% year-over-year revenue increase to $22.73M. Despite this growth, the company recorded a net loss of ($2.91M) and a diluted loss per share of ($0.64). The revenue growth was primarily driven by increased …

A New Arcus Employee Receives Options With a $28.72 Exercise Price

Arcus Biosciences (NYSE: RCUS) announced that its Compensation Committee granted a new employee options to purchase 2,850 shares of common stock at an exercise price of $28.72 per share, which was the closing price on August 10, 2026. The employee also received restricted stock …